[Clinical and pharmacokinetic studies of gentamicin in intravenous drip infusion to children]. 1988

H Sakata, and C Ishida, and H Kakehashi, and K Fujita, and H Yoshioka, and Y Mori, and S Maruyama, and Y Sakata, and M Takimoto
Department of Pediatrics, Asahikawa Medical College.

Eighteen children with urinary tract infection were treated with intravenous drip infusion of gentamicin (GM), and clinical efficacy and pharmacokinetics were studied. Ages of the patients ranged from 2 months to 12 years. Doses of GM ranged 1.0 to 2.5 mg/kg every 8 to 12 hours, and treatment continued for 4 to 10 days. Among 18 patients treated, clinical results were excellent in 12, and good in 6. Values of BUN and creatinine remained within normal range in all patients during and after the GM treatment. One child had an eosinophilia. There were no cases that showed signs and symptoms of oto- and nephrotoxicity. Twenty eight time-serum level curves were studied in 16 patients during and after intravenous infusion of GM over 30 minutes. Doses were 1.0 mg/kg in 4, 1.9-2.0 mg/kg in 14, and 2.2-2.5 mg/kg in 10. Peak serum levels at 30 minutes after the start of infusion were 2.66-7.38 micrograms/ml (average 5.45 micrograms/ml) in cases receiving 1.0 mg/kg, 4.67-10.8 micrograms/ml (7.26 micrograms/ml) in 1.9-2.0 mg/kg, and 6.16-16.5 micrograms/ml (8.86 micrograms/ml) in 2.2-2.5 mg/kg. Elimination half-lives were 1.75-2.48 hours (average 2.10 hours) in cases with ages less than 1 year, 1.58-2.58 hours (2.01 hours) with 1 to 6 years, and 1.20-3.07 hours (1.66 hours) with 7 to 12 years who were given doses of 1.9-2.5 mg/kg. There were no significant differences in pharmacokinetic parameters between first and last administration in these patients, suggesting that no accumulation occurred with above mentioned doses. Urinary recovery of GM ranged from 21.9 to 99.2 percent (average 62.48%) within 6.5 hours after the initiation of drip infusion.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014552 Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA. Infection, Urinary Tract,Infections, Urinary Tract,Tract Infection, Urinary,Tract Infections, Urinary,Urinary Tract Infection

Related Publications

H Sakata, and C Ishida, and H Kakehashi, and K Fujita, and H Yoshioka, and Y Mori, and S Maruyama, and Y Sakata, and M Takimoto
January 1983, The Japanese journal of antibiotics,
H Sakata, and C Ishida, and H Kakehashi, and K Fujita, and H Yoshioka, and Y Mori, and S Maruyama, and Y Sakata, and M Takimoto
January 1983, The Japanese journal of antibiotics,
H Sakata, and C Ishida, and H Kakehashi, and K Fujita, and H Yoshioka, and Y Mori, and S Maruyama, and Y Sakata, and M Takimoto
June 1985, The Japanese journal of antibiotics,
H Sakata, and C Ishida, and H Kakehashi, and K Fujita, and H Yoshioka, and Y Mori, and S Maruyama, and Y Sakata, and M Takimoto
October 1985, The Japanese journal of antibiotics,
H Sakata, and C Ishida, and H Kakehashi, and K Fujita, and H Yoshioka, and Y Mori, and S Maruyama, and Y Sakata, and M Takimoto
November 1986, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
H Sakata, and C Ishida, and H Kakehashi, and K Fujita, and H Yoshioka, and Y Mori, and S Maruyama, and Y Sakata, and M Takimoto
April 1984, The Japanese journal of antibiotics,
H Sakata, and C Ishida, and H Kakehashi, and K Fujita, and H Yoshioka, and Y Mori, and S Maruyama, and Y Sakata, and M Takimoto
December 2011, The Japanese journal of antibiotics,
H Sakata, and C Ishida, and H Kakehashi, and K Fujita, and H Yoshioka, and Y Mori, and S Maruyama, and Y Sakata, and M Takimoto
September 1981, The Japanese journal of antibiotics,
H Sakata, and C Ishida, and H Kakehashi, and K Fujita, and H Yoshioka, and Y Mori, and S Maruyama, and Y Sakata, and M Takimoto
February 1983, The Japanese journal of antibiotics,
H Sakata, and C Ishida, and H Kakehashi, and K Fujita, and H Yoshioka, and Y Mori, and S Maruyama, and Y Sakata, and M Takimoto
January 1984, The Japanese journal of antibiotics,
Copied contents to your clipboard!